Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from November 4, 2025

Partial Published before the outcome was known, scored automatically when the window closed on February 2, 2026 — +9.1% at the close.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted

$66.50 – $68.50Entry zone — fair-value band

$68.24Published — price the day we called it

$80.52Target — the price the thesis aimed for

$75.59Peak — highest point inside the window, not a realized return

$74.45Window close — end-of-window price, context only

What happened

Partial

Reached 60% of the predicted growth at its peak, without hitting the target.

At window close

+9.1%

realized, from the publication price to the last close inside the window

Peak gain

+10.8%

peak, from the publication price — not a realized return

S&P 500, same window

+3.3%

SPY over the identical days, dividend-adjusted

Window close

$74.45

last close inside the window, ended February 2, 2026

Peak price

$75.59

peak on January 7, 2026 — not a realized return

Days to target

—

The thesis — published November 4, 2025

Predicted growth

+18%

over the measurement window

Target price

$80.52

the price the thesis aimed for

Entry zone

$66.50 – $68.50

the fair-value band we waited for

Price at publication

$68.24

published November 4, 2025

Confidence

86%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Halozyme looks set for near-term strength. More buyers than usual and an improving trend suggest buying small dips. Recent research kept a $90 target and sees a good chance the next quarter beats expectations. The Elektrofi deal adds more ways to deliver medicines. Royalties keep stacking up, giving clearer income. A 0-3 month climb from recent price areas is likely, though biotech stocks can swing sharply.

Primary drivers

Royalties from ENHANZE add steady profit power over the next few quarters
Analyst H.C. Wainwright kept a $90 target, signaling continued confidence
Improving trend with lots more buying than usual in recent trading
Elektrofi purchase widens drug-delivery tools HALO offers its partners

How it played out

HALO: rose but stayed below the target

Lyra published HALO at $68.24 on 2025-11-04 with an 18% expected gain and a $80.52 target. The thesis expected a 0-3 month climb. It pointed to ENHANZE royalties, an H.C. Wainwright $90 target, heavier buying, an improving trend, and the Elektrofi deal adding more drug-delivery tools.

Inside the window from 2025-11-04 to 2026-02-02, HALO peaked at $75.59 on 2026-01-07. The peak gain was 10.8%, but the stock never reached $80.52. It ended at $74.45. The thesis partially played out: direction was right, but the target was missed.

What happened during the window

On 2025-11-12, Investor's Business Daily reported that HALO's Relative Strength Rating rose to 82 from 69. On 2025-12-26, it reported that the rating later rose to 75 from 69 while the stock was still below a cited 79.50 buy point.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals